Literature DB >> 26094310

Virus Like Particles as Immunogens and Universal Nanocarriers.

Antonina Naskalska, Krzysztof Pyrć.   

Abstract

Over the last two decades virus-like particles (VLPs) have become an important tool in biomedical research and medicine. VLPs are multiprotein structures that resemble viable virus particles in conformation but lack the viral genome. Consequently, they are non-infectious and non-replicative, but retain the ability to penetrate cells, making them useful for a vast spectrum of applications. Above all, VLPs mimicking genuine viruses in antigenic structure provide a safe alternative to attenuated and inactivated viruses in vaccine development. Moreover, due to their transducing proprieties, VLPs may efficiently deliver foreign nucleic acids, proteins, or conjugated compounds to the organism, or even to specific cell types. Additionally, VLPs are versatile nanovectors due to their flexibility in terms of composition and expression systems. In this review, different approaches for of virus-like particle synthesis and manipulation, as well as their potential applications, will be discussed.

Mesh:

Substances:

Year:  2015        PMID: 26094310

Source DB:  PubMed          Journal:  Pol J Microbiol        ISSN: 1733-1331


  17 in total

1.  Physalis Mottle Virus-Like Particles as Nanocarriers for Imaging Reagents and Drugs.

Authors:  Hema Masarapu; Bindi K Patel; Paul L Chariou; He Hu; Neetu M Gulati; Bradley L Carpenter; Reza A Ghiladi; Sourabh Shukla; Nicole F Steinmetz
Journal:  Biomacromolecules       Date:  2017-11-16       Impact factor: 6.988

2.  Identification of HIV-1-Based Virus-like Particles by Multifrequency Atomic Force Microscopy.

Authors:  Irene González-Domínguez; Sonia Gutiérrez-Granados; Laura Cervera; Francesc Gòdia; Neus Domingo
Journal:  Biophys J       Date:  2016-09-20       Impact factor: 4.033

3.  Engineering the PP7 Virus Capsid as a Peptide Display Platform.

Authors:  Liangjun Zhao; Mykhailo Kopylov; Clinton S Potter; Bridget Carragher; M G Finn
Journal:  ACS Nano       Date:  2019-03-26       Impact factor: 15.881

Review 4.  Nanoimmunoengineering strategies in cancer diagnosis and therapy.

Authors:  Robabehbeygom Ghafelehbashi; Melina Farshbafnadi; Niloofar Shokraneh Aghdam; Shahin Amiri; Mitra Salehi; Sepideh Razi
Journal:  Clin Transl Oncol       Date:  2022-09-08       Impact factor: 3.340

5.  VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation.

Authors:  Seth M Daly; Jason A Joyner; Kathleen D Triplett; Bradley O Elmore; Srijana Pokhrel; Kathryn M Frietze; David S Peabody; Bryce Chackerian; Pamela R Hall
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

Review 6.  Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.

Authors:  Chongbo Zhao; Zhujun Ao; Xiaojian Yao
Journal:  Vaccines (Basel)       Date:  2016-01-22

Review 7.  Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation.

Authors:  Saborni Chattopadhyay; Jui-Yi Chen; Hui-Wen Chen; Che-Ming Jack Hu
Journal:  Nanotheranostics       Date:  2017-06-09

Review 8.  Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies.

Authors:  Kelly M Hainline; Chelsea N Fries; Joel H Collier
Journal:  Adv Healthc Mater       Date:  2017-11-08       Impact factor: 9.933

9.  Novel coronavirus-like particles targeting cells lining the respiratory tract.

Authors:  Antonina Naskalska; Agnieszka Dabrowska; Paulina Nowak; Artur Szczepanski; Krzysztof Jasik; Aleksandra Milewska; Marek Ochman; Slawomir Zeglen; Zenon Rajfur; Krzysztof Pyrc
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

10.  Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins.

Authors:  Marianela C Serradell; Lucía L Rupil; Román A Martino; César G Prucca; Pedro G Carranza; Alicia Saura; Elmer A Fernández; Pablo R Gargantini; Albano H Tenaglia; Juan P Petiti; Renata R Tonelli; Nicolás Reinoso-Vizcaino; José Echenique; Luciana Berod; Eliane Piaggio; Bertrand Bellier; Tim Sparwasser; David Klatzmann; Hugo D Luján
Journal:  Nat Commun       Date:  2019-01-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.